Infectious Disease

FDA approved ensitrelvir for COVID-19 postexposure prophylaxis in adults and adolescents aged 12 years and older after exposure.

A validated AI phenotyping tool identified chronic long COVID burden missed by ICD surveillance in nearly 460,000 COVID-19 patients.

FDA approved bulevirtide-gmod (Hepcludex; Gilead Sciences) for adults with chronic HDV infection without cirrhosis or with compensated cirrhosis, based on phase 3 data.

A 5-day course of ensitrelvir reduced symptomatic COVID-19 risk by 67% after household exposure in the phase 3 SCORPIO-PEP trial.

ACOG 2026: Kathryn Miele, MD, discusses syphilis screening in pregnancy and how clinicians can reduce stigma around testing.

ACOG 2026: Kathryn Miele, MD, discusses syphilis titer interpretation, discordant results, partner treatment, and practical resources for primary care clinicians.

FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.

FDA approves doravirine/islatravir for adults with virologically suppressed HIV-1, offering a once-daily 2-drug regimen with noninferior efficacy.

Test your knowledge of 2024 CDC STI data on high-risk populations and what it means for your screening decisions.

Test your knowledge of 2024 syphilis trends, staging distribution, and declines in primary and secondary disease.

Try your hand at these 5 questions on the latest US CDC STI data.

Expert discussion on how updated guidelines

Expert discussion on how updated guidelines intersect with state vaccination requirements for school entry.

Expert discussion on how vaccine education continues to play a significant role in immunization uptake and improving health equity.

Experts discuss the potential unintended consequences of less children getting immunized if the current trends continue.

Experts discuss the potential unintended consequences of less children getting immunized if the current trends continue.

In this episode of our roundtable discussion, four experts talk about the changes to the CDC’s ACIP meetings.

Experts review recent updates to the US childhood immunization schedule, including RSV prevention, hepatitis B birth dose changes, and expanded shared clinical decision making.

CROI 2026: Phase III data show once-daily Eslatravir/Ravin matches BFTAF in treatment‑naive HIV, achieving high viral suppression at 48 weeks.

ACP updates RSV vaccine guidance: adults 75+ get a one-time protein subunit shot; higher-risk ages 60–74 may consider it to prevent hospitalization.

HIV specialist Jürgen Rockstroh, MD, discusses the importance of PrEP being more accessible through primary care physicians.

SMART trial finds clesrovimab protects high-risk children in a second RSV season, with consistent safety and fewer RSV-related hospitalizations.

Real-world data show GSK’s Arexvy is linked to 75.6% lower hospitalization risk in adults ≥60, with reduced CV events and COPD exacerbations.

Dr Hatfield shares a case of a patient living in shared housing who was concerned about her housemates seeing her PrEP medication.

ACON Laboratories launches the first FDA-cleared at-home test for RSV, influenza, and COVID-19, enhancing respiratory symptom management for families.